Computer Guided Microwave Liver Ablation for Liver Cancer
This study is investigating if using a computer guidance software, called Accublate, during microwave liver ablation (a procedure that uses heat to destroy tumors) can improve treatment for hepatocellular carcinoma (HCC), a type of liver cancer. The software helps doctors see a real-time simulation of the ablation, showing which parts of the tumor have been treated. The main goals are to see if this computer guidance reduces incomplete tumor treatments and lowers the rate of cancer recurrence after two years. It also aims to track any changes in medical problems for participants using the software. You might be eligible if you are an adult aged 18-90 with HCC that can be treated with this type of ablation, and meet other specific criteria. The study's current status is unclear.
- Study design
- This interventional study plans to enroll 84 participants. It will evaluate the use of Computer-Assisted Microwave Liver Ablation.
- What's involved
- You would undergo a CT-guided microwave ablation procedure. Your progress will be assessed at imaging follow-up visits every 3 months, up to 24 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for local tumor progression at each imaging follow-up visit (every 3 months, up to 24 months) and for technical effectiveness at 1 month post-procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Computer Guided Microwave Liver Ablation
At a glance
Conditions
NCT07226869
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Dartmouth HItchcock Medical Center
Lebanon, New Hampshirestudy coordinator listed
Recruiting
Massachusetts General Hospital
Boston, Massachusettsstudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Andrea Borsic, PHD · STUDY_DIRECTOR · NE Scientific INC
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Local Tumor ProgressionAssessed at each imaging follow-up visit ( at every 3 months, up to 24 months).
Local Tumor Progression (LTP) is defined as the appearance of new or enlarging nodular or irregular arterial phase enhancement with washout at or within the edge of a previously ablated lesion after an earlier imaging study has demonstrated complete ablation (technical effectiveness). LTP is determined on serial contrast-enhanced CT or MRI according to LI-RADS treatment response criteria or equivalent institutional standards.
- Technical Effectiveness1 month post-procedure
Technical Effectiveness is defined as complete ablation of all target tumor tissue, demonstrated by the absence of any nodular or irregular arterial phase enhancement within or along the margin of the ablation zone on the first post-ablation contrast-enhanced imaging study (CT or MRI). This assessment is performed approximately one month after the procedure. Imaging is interpreted according to LI-RADS treatment response criteria (LR-TR) or equivalent institutional criteria.